GeneDx (WGS) Projected to Post Quarterly Earnings on Tuesday

GeneDx (NASDAQ:WGS) is anticipated to announce its Q3 2025 results before the market opens on Tuesday, October 28th. Analysts expect the company to announce earnings of $0.33 per share and revenue of $104.3250 million for the quarter. GeneDx has set its FY 2025 guidance at EPS.Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, October 28, 2025 at 8:30 AM ET.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.40. The business had revenue of $102.69 million for the quarter, compared to analysts’ expectations of $86.00 million. GeneDx had a return on equity of 16.51% and a net margin of 0.39%. On average, analysts expect GeneDx to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

GeneDx Price Performance

Shares of GeneDx stock opened at $128.87 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.87 and a quick ratio of 2.70. The business’s 50 day simple moving average is $123.22 and its two-hundred day simple moving average is $97.73. The stock has a market capitalization of $3.70 billion, a P/E ratio of 2,577.40 and a beta of 1.98. GeneDx has a one year low of $55.17 and a one year high of $136.00.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on WGS shares. Zacks Research lowered GeneDx from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 2nd. BTIG Research lifted their price objective on GeneDx from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, October 22nd. Weiss Ratings reiterated a “sell (d)” rating on shares of GeneDx in a research report on Friday. Wells Fargo & Company lifted their price objective on GeneDx from $78.00 to $95.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 30th. Finally, Piper Sandler lifted their price objective on GeneDx from $120.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, September 11th. Eight investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, GeneDx currently has an average rating of “Moderate Buy” and a consensus target price of $112.80.

Insider Transactions at GeneDx

In related news, CFO Kevin Feeley sold 3,728 shares of GeneDx stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total transaction of $452,840.16. Following the sale, the chief financial officer directly owned 8,755 shares in the company, valued at $1,063,469.85. The trade was a 29.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Katherine Stueland sold 10,501 shares of the business’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $121.47, for a total value of $1,275,556.47. Following the completion of the sale, the chief executive officer directly owned 14,578 shares in the company, valued at $1,770,789.66. This trade represents a 41.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 556,371 shares of company stock valued at $67,489,314. Company insiders own 29.60% of the company’s stock.

Institutional Investors Weigh In On GeneDx

Several hedge funds have recently added to or reduced their stakes in WGS. Invesco Ltd. boosted its holdings in GeneDx by 42.3% in the second quarter. Invesco Ltd. now owns 554,419 shares of the company’s stock worth $51,178,000 after acquiring an additional 164,840 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of GeneDx by 76.2% during the second quarter. Ameriprise Financial Inc. now owns 255,931 shares of the company’s stock valued at $23,625,000 after purchasing an additional 110,684 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of GeneDx by 156.8% during the second quarter. Bank of America Corp DE now owns 156,226 shares of the company’s stock valued at $14,421,000 after purchasing an additional 95,389 shares in the last quarter. AXA S.A. bought a new position in shares of GeneDx during the second quarter valued at $8,148,000. Finally, Raymond James Financial Inc. lifted its holdings in shares of GeneDx by 24.0% during the second quarter. Raymond James Financial Inc. now owns 413,223 shares of the company’s stock valued at $38,145,000 after purchasing an additional 79,847 shares in the last quarter. 61.72% of the stock is owned by institutional investors.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.